Axoltis Pharma today announces the closing of a Series A funding round worth €18 million ($20.9M), to be disbursed in two installments. The funding, which includes new and historic investors, will enable the company to pursue the development of NX210c, its lead drug candidate, currently in phase 2 clinical trials in patients with ALS (Amyotrophic … Read more
Axoltis Pharma lance une campagne d’investissement participatif sur la plateforme Capital Cell. Cette opération s’inscrit dans un tour de financement destiné à accélérer le développement de NX210c, son candidat-médicament actuellement en fin de phase 2 d’essai clinique chez des patients atteints de sclérose latérale amyotrophique (SLA, ou maladie de Charcot). Communiqué de Presse
By Yann Godfrin
Serial entrepreneur in biotech, Mr. Lafay’s decades of experience, his vision and network will bolster Axoltis’ strategic corporate development. Read More (Download PDF English / Français )
By Yann Godfrin
Phase II trial will assess efficacy and tolerability of NX210c in Amyotrophic Lateral Sclerosis (ALS) patients 80 patients due to be enrolled with first results expected in early 2026 NX210c drug candidate allows for promising approach to repairing Blood Brain Barrier (BBB) which is impaired in neurodegenerative diseases such as ALS Read more (Download PDF … Read more
By Yann Godfrin
Good safety profile and significant pharmacological effects confirmNX210c drug candidate properties and potential to address broad range of neurodegenerative diseases Biomarkers reveal significant and sustained effects confirming NX210c’saction on integrity and repair of Blood Brain Barrier (BBB), as well as fundamental pathways in neuroprotection and neurotransmission In 2024, Axoltis plans to initiate phase 2 trial … Read more
By Yann Godfrin
July 27th, 2023 Milan, Lyon InSilicoTrials, a leading provider of artificial intelligence (AI) and simulation tools for drug and medical device development, has embarked on a collaborative partnership with Axoltis Pharma, a biopharmaceutical company committed to developing disease-modifying drugs for patients with high unmet medical needs in neurodegenerative and traumatic neurologic impairments. This strategic collaboration … Read more